Cambridge Investment Research Advisors, Inc. Exelixis, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.4 Billion
- Q3 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 150,230 shares of EXEL stock, worth $4.98 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
150,230
Previous 157,905
4.86%
Holding current value
$4.98 Million
Previous $3.55 Million
9.86%
% of portfolio
0.01%
Previous 0.01%
Shares
31 transactions
Others Institutions Holding EXEL
# of Institutions
520Shares Held
244MCall Options Held
2.84MPut Options Held
2.29M-
Black Rock Inc. New York, NY33.5MShares$1.11 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.3MShares$972 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA25.4MShares$842 Million3.31% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.4MShares$509 Million0.63% of portfolio
-
State Street Corp Boston, MA11.4MShares$379 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $10.7B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...